Science and technology company Danaher Corporation (NYSE:DHR) revealed on Friday the launch of a definitive agreement to acquire Integrated DNA Technologies (IDT) for an undisclosed amount.
Founded by Joseph Walder, MD, PhD, IDT develops, manufactures and markets nucleic acid products for the life sciences industry in academic research, biotechnology, agriculture, medical diagnostics and pharmaceutical development. Its primary business is the manufacturing of high-quality, custom DNA and RNA oligonucleotides and has more than 1,200 employees and over 100,000 customers worldwide.
Upon closing, IDT will operate as a standalone operating company and brand within Danaher's Life Sciences platform.
The transaction, which is expected to close mid-year 2018, is subject to customary closing conditions and regulatory approvals.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial